Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. (Nasdaq: AMHC) is a clinical-stage biopharmaceutical company that completed its de-SPAC business combination with Amplitude Healthcare Acquisition Corporation, sponsored by Amplitude Healthcare Holdings, LLC, following the blank-check vehicle's initial public offering in 2021. The company operates in the biotechnology and life sciences sector, concentrating on antibody-based therapies for hematopoietic stem cell transplantation conditioning and mast cell-driven diseases, with its lead anti-c-Kit antibody program advancing through clinical development. On July 3, 2025, Jasper Therapeutics filed an 8-K current report with the SEC under accession number 0001213900-25-061471. Sign up on SpacDesk for full data on this filing and comprehensive coverage of the SPAC universe.